Why Eli Lilly shares should be higher

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

Why Eli Lilly shares should be higher

TL;DR

  • November's consumer price index report showed inflation at 2.7%, below the estimated 3.1%, leading to a higher stock market.
  • Micron's stock surged 11% after an earnings beat, revitalizing the AI trade.
  • OpenAI is reportedly in talks to raise new funding at a valuation of around $750 billion.
  • Eli Lilly announced positive topline results from a Phase 3 study for its oral GLP-1 drug, Orforglipron, for weight maintenance.
  • Eli Lilly submitted Orforglipron to the FDA for obesity treatment.
  • Nike shares increased ahead of its quarterly earnings report, with analysts expecting a solid quarter but cautious guidance.
  • Investors will focus on Nike's inventory clean-up and wholesale channel sales, as well as updates on China's recovery.
  • Other stocks mentioned in a rapid-fire segment included Darden Restaurants, Lululemon, Sherwin-Williams, Shake Shack, and Merck.